Print this page
-
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
-
Shridar Ganesan
Applicable Disease Sites: Any Site -
AYA Cancer Survivor and Parent Communication and Transition Readiness
Protocol: 002308Principal Investigator:
-
Maria Venetis
Applicable Disease Sites: Any Site -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site
-
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.
Protocol: 082203Principal Investigator:
-
Ryan Stephenson
Applicable Disease Sites: Kidney -
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma.
Protocol: 092204Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
Concordance of Self-reported Race and Ethnicity with Hospital Records Among Pediatric Patients.
Protocol: 112001Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Any Site -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.
Protocol: 112103Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Soft Tissue